QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:PMD

Psychemedics (PMD) Stock Price, News & Analysis

$2.93
-0.07 (-2.33%)
(As of 04:38 PM ET)
Today's Range
$2.88
$3.00
50-Day Range
$2.92
$3.40
52-Week Range
$2.06
$5.63
Volume
14,242 shs
Average Volume
12,929 shs
Market Capitalization
$16.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PMD stock logo

About Psychemedics Stock (NASDAQ:PMD)

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.

PMD Stock Price History

PMD Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Psychemedics reports Q3 results
Psychemedics Corp PMD
Psychemedics Eliminates Dividend
See More Headlines
Receive PMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/23/2019
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:PMD
Employees
133
Year Founded
1985

Profitability

Net Income
$-1,080,000.00
Pretax Margin
-12.82%

Debt

Sales & Book Value

Annual Sales
$25.24 million
Cash Flow
$0.40 per share
Book Value
$1.91 per share

Miscellaneous

Free Float
4,410,000
Market Cap
$17.69 million
Optionable
Not Optionable
Beta
0.64

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Brian Hullinger
    President, CEO & Director
  • Dr. Werner A. Baumgartner Ph.D.
    Founder
  • Ms. Annette Baumgartner
    Founder
  • Daniella Mehalik
    Vice President of Finance
  • Mr. Michael Weisenhoff (Age 34)
    Principal Financial & Accounting Manager
  • Ms. Shannon Shoemaker
    Chief Revenue Officer
  • Mr. Patrick J. Kinney Jr.
    Secretary

PMD Stock Analysis - Frequently Asked Questions

How have PMD shares performed in 2024?

Psychemedics' stock was trading at $2.96 on January 1st, 2024. Since then, PMD stock has decreased by 0.3% and is now trading at $2.95.
View the best growth stocks for 2024 here
.

Are investors shorting Psychemedics?

Psychemedics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 14,800 shares, an increase of 27.6% from the February 29th total of 11,600 shares. Based on an average daily trading volume, of 13,300 shares, the short-interest ratio is currently 1.1 days. Currently, 0.4% of the company's stock are sold short.
View Psychemedics' Short Interest
.

When is Psychemedics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our PMD earnings forecast
.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) announced its quarterly earnings results on Tuesday, April, 23rd. The company reported $0.11 earnings per share (EPS) for the quarter. The company earned $9.82 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 40.62% and a negative net margin of 16.69%.

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics declared a quarterly dividend on Tuesday, May 9th. Shareholders of record on Thursday, May 25th will be paid a dividend of $0.07 per share on Thursday, June 8th. This represents a $0.28 annualized dividend and a dividend yield of 9.49%. The ex-dividend date is Wednesday, May 24th.
Read our dividend analysis for PMD
.

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.28%). Insiders that own company stock include Charles M Doucot and Peter Kamin.
View institutional ownership trends
.

How do I buy shares of Psychemedics?

Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PMD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners